Effect of dorzolamide and latanoprost on intraocular pressure after small incision cataract surgery

J Cataract Refract Surg. 1999 Dec;25(12):1624-9. doi: 10.1016/s0886-3350(99)00260-6.

Abstract

Purpose: To evaluate the effect of dorzolamide 2% and latanoprost 0.005% on intraocular pressure (IOP) after small incision cataract surgery.

Setting: Department of Ophthalmology, University of Vienna, Vienna, Austria.

Methods: This prospective study comprised 102 eyes of 102 consecutive patients scheduled for small incision cataract surgery. The patients were assigned preoperatively to 1 of 3 groups of 34 each: dorzolamide, latanoprost, and control (no treatment). One drop of the assigned medication was instilled immediately after surgery. Intraocular pressure was measured preoperatively and 6 and 20 to 24 hours postoperatively.

Results: Six hours after surgery, the mean increase in IOP was 1.9 mm Hg +/- 3.9 (SD) in the dorzolamide group (P = .004 versus control), 2.2 +/- 3.0 mm Hg in the latanoprost group (P = .005 versus control), and 4.8 +/- 5.2 mm Hg in the control group. Twenty to 24 hours postoperatively, IOP decreased a mean of -0.9 +/- 3.5 mm Hg in the dorzolamide group (P = .012 versus control) and increased a mean of 0.3 +/- 3.6 mm Hg in the latanoprost group (P = 0.24 versus control) and 1.3 +/- 4.2 mm Hg in the control group. One eye in the dorzolamide group, 1 eye in the latanoprost group, and 4 eyes in the control group had an IOP of 30 mm Hg or higher 6 hours postoperatively.

Conclusion: Six hours postoperatively, dorzolamide and latanoprost were effective in reducing the IOP increase after small incision cataract surgery; however, at 20 to 24 hours, only dorzolamide was effective. Neither drug prevented IOP spikes of 30 mm Hg or higher.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Carbonic Anhydrase Inhibitors / administration & dosage
  • Carbonic Anhydrase Inhibitors / therapeutic use*
  • Cataract Extraction* / adverse effects
  • Drug Therapy, Combination
  • Female
  • Humans
  • Intraocular Pressure / drug effects*
  • Latanoprost
  • Lens Implantation, Intraocular
  • Male
  • Minimally Invasive Surgical Procedures
  • Ocular Hypertension / etiology
  • Ocular Hypertension / prevention & control
  • Ophthalmic Solutions / administration & dosage
  • Ophthalmic Solutions / therapeutic use
  • Prospective Studies
  • Prostaglandins F, Synthetic / administration & dosage
  • Prostaglandins F, Synthetic / therapeutic use*
  • Sulfonamides / administration & dosage
  • Sulfonamides / therapeutic use*
  • Thiophenes / administration & dosage
  • Thiophenes / therapeutic use*
  • Treatment Outcome

Substances

  • Carbonic Anhydrase Inhibitors
  • Ophthalmic Solutions
  • Prostaglandins F, Synthetic
  • Sulfonamides
  • Thiophenes
  • Latanoprost
  • dorzolamide